Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter
2019 · Journal of the American Academy of Dermatology · 84 citations
https://doi.org/10.1016/j.jaad.2019.09.075
E
Emily S. Ruiz
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
194
Papers
2.9K
Citations
25
h-index
49
i10-index
Emily S. Ruiz is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Nonmelanoma Skin Cancer Studies & Cutaneous Melanoma Detection and Management & Cancer and Skin Lesions. The author has an h-index of 25, co-authored 165 publications.
ORCID: 0000-0001-5824-2721Papers by this author
worksField cancerization: Treatment
2020 · Journal of the American Academy of Dermatology · 63 citations
https://doi.org/10.1016/j.jaad.2020.03.127
Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
2020 · British Journal of Cancer · 62 citations
https://doi.org/10.1038/s41416-020-01044-8
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
2024 · Journal of Clinical Oncology · 56 citations
https://doi.org/10.1200/jco.23.01498
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
2022 · Journal for ImmunoTherapy of Cancer · 36 citations
https://doi.org/10.1136/jitc-2021-004434
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
2023 · Annals of Oncology · 35 citations
https://doi.org/10.1016/j.annonc.2023.10.123
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat